1-3 of 3
Leslie Bucheit
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B036: Pathway repression in progression on osimertinib therapy in NSCLC via a comprehensive genomic and epigenomic circulating tumor DNA (ctDNA) assay

Aaron Hardin, Leslie Bucheit, Amar Das, Craig Eagel, Helmy Eltoukhy
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B036.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B036
Published: 13 November 2024
View article titled, Abstract B036: Pathway repression in progression on osimertinib therapy in NSCLC via a comprehensive genomic and epigenomic circulating tumor DNA (ctDNA) assay
Journal Articles

Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study

Susanna Slater, Annette Bryant, Maria Aresu, Ruwaida Begum, Hsiang-Chi Chen, Clare Peckitt, Retchel Lazaro-Alcausi, Paul Carter, Gayathri Anandappa, Shelize Khakoo, Lucinda Melcher, Vanessa Potter, Francisca M. Marti, Joesph Huang, Graham Branagan, Nicol George, Muti Abulafi, Sarah Duff, Ashraf Raja, Ashish Gupta, Nicholas West, Leslie Bucheit, Thereasa Rich, Ian Chau, David Cunningham, Naureen Starling, for the TRACC Part B trial investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3459–3469.
https://doi.org/10.1158/1078-0432.CCR-24-0226
Published: 15 August 2024
View article titled, Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study
Open the PDF for Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View article titled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data